This site is intended for Canadian healthcare professionals.
Select Language | Sélectionnez une langue
GA CHANGES LIVES
GA CHANGES LIVES

Fear of Vision Loss

Patients with GA fear missing out on important life events and losing their independence.2,3

Patients Suffer From

Distorted vision4 and scotoma5

Distorted vision4 and scotoma5

Central field defect6


Central field defect6


Vision loss6


Vision loss6


Which Leads to Patients Worrying About

Missing meaningful life events2,3,4,7


Missing meaningful life events2,3,4,7


Being unable to complete everyday tasks1,7

Being unable to complete everyday tasks1,7

Loss of independence 
(e.g., difficulty driving)1,3,4,7

Loss of independence
(e.g., difficulty driving)1,3,4,7

Patients Lose More Than Just Vision

Report difficulty reading1


Report difficulty reading1


Lose their confidence driving 
at night7


Lose their confidence driving
at night7


Of those with bilateral GA lose 
their ability to drive within 1.6 years after diagnosis3*

Of those with bilateral GA lose
their ability to drive within 1.6 years after diagnosis3*

Visual Acuity ≠ Visual Function

GA progression is highly variable among individual patients.8

Functional Tests to Assess GA

Functional Tests to Assess GA

GA progression is not always correlated with visual acuity, and changes in visual function can occur even before a decline in visual acuity.5,8

Monitoring for GA must go beyond BCVA tests alone, which makes functional assessments of vision critical when determining impact on patients. These include: contrast sensitivity, LLVA, dark adaptation, and microperimetry.5,8

Multiple Potential Pathways and Stressors

Multiple Potential Pathways and Stressors

have been posited in the pathogenesis of geographic atrophy.5,6

  • *Findings from a UK retrospective cohort analysis with patients with visual acuity (VA) follow-up. The patients were eligible to drive at baseline according to the UK driving standard (VA measure >70 letters or Snellen 6/12 [US Snellen 20/40] in the better-seeing eye) but lost their vision progressively making them ineligible to drive; 1.6 years represents the median (0.7-2.7 years).3

References:

  1. Singh RP, et al. Am J Ophthalmol Clin Trials. 2019;2(1):1-6.

  2. Sayegh RG, et al. Am J Ophthalmol. 2017;179:118-128.

  3. Chakravarthy U, et al. Ophthalmology. 2018;125(6):842-849.

  4. Carlton J, Barnes S, Haywood A. Br Ir Orthopt J. 2019;15(1):133-141.

  5. Holz FG, et al. Ophthalmology. 2014;121(5):1079-1091.

  6. Rajanala K, et al. Front Ophthalmol (Lausanne). 2023;3:1327883.

  7. Patel PJ, et al. Clin Ophthalmol. 2020;14:15-28.

  8. Fleckenstein M, et al. Ophthalmology. 2018:125(3):369-390.

  9. Lindblad AS, et al. Arch Ophthalmol. 2009;127(9):1168-1174.

  10. Meleth AD, et al. Invest Ophthalmol Vis Sci. 2011;52(2):1119-1126.